

2017

1. **Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).** Wermke M, Schuster C, Nolte F, Al-Ali HK, Kiewe P, Schönfeldt C, Jakob C, von Bonin M, Hentschel L, Klut IM, Ehninger G, Bornhäuser M, Baretton G, Germing U, Herbst R, Haase D, Hofmann WK, Platzbecker U. *Br J Haematol.* 2016 Dec;175(5):917-924.
2. **Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.** Balaian E, Schuster C, Schönfeldt C, Germing U, Haase D, Tuve S, Ordemann R, Ehninger G, Bornhäuser M, Oelschlaegel U, Mohr B, von Bonin M, Platzbecker U, Wermke M. *Ann Hematol.* 2016 Oct;95(11):1805-10.
3. **Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).** Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T. *J Clin Oncol.* 2017 May 2;in press
4. **Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.** de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N. *Blood.* 2017 Mar 30;129(13):1753-1762.
5. **Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.** Radsak M, Platzbecker U, Schmidt CS, Hofmann WK, Nolte F. *Eur J Haematol.* 2017 Mar 21. In press
6. **Myelodysplastic syndromes and bone loss in mice and men.** Weidner H, Rauner M, Trautmann F, Schmitt J, Balaian E, Mies A, Helas S, Baschant U, Khandanpour C, Bornhäuser M, Hofbauer LC, Platzbecker U. *Leukemia.* 2017 Apr;31(4):1003-1007.
7. **Allogeneic Stem Cell Transplantation for Patients Age \geq 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.** Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen DW, Tischer J, Nagler A, Glass B, Maertens J, Yáñez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachée P, Selleslag D, de Witte T, Robin M, Kröger N. *Biol Blood Marrow Transplant.* 2017 Jan;23(1):44-52.
8. **Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.** Garcia-Manero G, Almeida A, Giagounidis A, Platzbecker U, Garcia R, Voso MT, Larsen SR, Valcarcel D, Silverman LR, Skikne B, Santini V. *BMC Hematol.* 2016 May 3;16:12.

9. **Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.** Jann JC, Nowak D, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I, Xanthopoulos C, Fabarius A, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Schlenk R, Bug G, Lübbert M, Ganser A, Germing U, Haferlach C, Hofmann WK, Mossner M. *J Med Genet.* 2017 Jun 9. in press
10. **Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.** Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann WK, Giagounidis A, Götze K, Lübbert M, Schlenk RF, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schaffhausen P, Bug G, Brümmendorf TH, Haas R, Trümper L, Shirneshan K, Haase D. *Ann Hematol.* 2017 Jun;96(6):887-894.
11. **Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.** Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P. *J Clin Oncol.* 2017 May 10;35(14):1591-1597
12. **New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.** Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N, Bennett JM, Aul C, Germing U. *Leuk Res.* 2017 Feb 27;57:78-84.
13. **Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.** Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. *Blood.* 2016 Oct 20;128(16):2096-2097
14. **Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).** Bennett JM, Tuechler H, Aul C, Strupp C, Germing U. *Leuk Res.* 2016 Aug;47:63-9.
15. **GFI1 as a novel prognostic and therapeutic factor for AML/MDS.** Hönes JM, Botezatu L, Helness A, Vadnais C, Vassen L, Robert F, Hergenhan SM, Thivakaran A, Schütte J, Al-Matary YS, Lams RF, Fraszscak J, Makishima H, Radivoyevitch T, Przychodzen B, da Conceição Castro SV, Görgens A, Giebel B, Klein-Hitpass L, Lennartz K, Heuser M, Thiede C, Ehninger G, Dührsen U, Maciejewski JP, Möröy T, Khandanpour C. *Leukemia.* 2016 Jun;30(6):1237-45.
16. **Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.** Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Ali NA, Fenaux P, Gore SD, Komrokji R. *Oncotarget.* 2017 Jun 14.

17. **Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.** Heuser M, Gabdoulline R, Löffeld P, Dobbernack V, Kreimeyer H, Pankratz M, Flintrop M, Liebich A, Klesse S, Panagiota V, Stadler M, Wichmann M, Shahswar R, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Geffers R, Schlegelberger B, Göhring G, Kreipe HH, Germing U, Ganser A, Kröger N, Koenecke C, Thol F. *Ann Hematol.* 2017 Aug;96(8):1361-1372.